These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 16799407)
61. Molecular Aspects of Insulin Aggregation and Various Therapeutic Interventions. Das A; Shah M; Saraogi I ACS Bio Med Chem Au; 2022 Jun; 2(3):205-221. PubMed ID: 37101572 [TBL] [Abstract][Full Text] [Related]
62. The intriguing dose-dependent effect of selected amphiphilic compounds on insulin amyloid aggregation: Focus on a cholesterol-based detergent, Chobimalt. Siposova K; Petrenko VI; Garcarova I; Sedlakova D; Almásy L; Kyzyma OA; Kriechbaum M; Musatov A Front Mol Biosci; 2022; 9():955282. PubMed ID: 36060240 [TBL] [Abstract][Full Text] [Related]
63. Insulin Pump-related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes. Everett EM; Copeland TP; Moin T; Wisk LE J Clin Endocrinol Metab; 2022 May; 107(6):e2381-e2387. PubMed ID: 35196382 [TBL] [Abstract][Full Text] [Related]
64. Inflammation at Site of Insulin Infusion Diminishes Glycemic Control. Kesserwan S; Lewis BE; Mao L; Sharafieh R; Atwood T; Kreutzer DL; Klueh U J Pharm Sci; 2022 Jul; 111(7):1952-1961. PubMed ID: 34986358 [TBL] [Abstract][Full Text] [Related]
65. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. Poewe W; Stocchi F; Arkadir D; Ebersbach G; Ellenbogen AL; Giladi N; Isaacson SH; Kieburtz K; LeWitt P; Olanow CW; Simuni T; Thomas A; Zlotogorski A; Adar L; Case R; Oren S; Fuchs Orenbach S; Rosenfeld O; Sasson N; Yardeni T; Espay AJ; Mov Disord; 2021 Nov; 36(11):2687-2692. PubMed ID: 34496081 [TBL] [Abstract][Full Text] [Related]
66. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W; J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945 [TBL] [Abstract][Full Text] [Related]
67. Wirelessly Controlled Implantable System for On-demand and Pulsatile Insulin Administration. Lee SH; Ahn JW; Cho YC; Kim SN; Lee C; Ku GW; Bin Choy Y; Kim HC Sci Rep; 2019 Mar; 9(1):5009. PubMed ID: 30899066 [TBL] [Abstract][Full Text] [Related]
69. Inhibition of Insulin Amyloid Fibrillation by a Novel Amphipathic Heptapeptide: MECHANISTIC DETAILS STUDIED BY SPECTROSCOPY IN COMBINATION WITH MICROSCOPY. Ratha BN; Ghosh A; Brender JR; Gayen N; Ilyas H; Neeraja C; Das KP; Mandal AK; Bhunia A J Biol Chem; 2016 Nov; 291(45):23545-23556. PubMed ID: 27679488 [TBL] [Abstract][Full Text] [Related]
70. A Continuous Subcutaneous Insulin Infusion Needle Break. George MM; Ruiz-Elizalde AR; Beck JK Clin Diabetes; 2015 Oct; 33(4):195-7. PubMed ID: 26487795 [No Abstract] [Full Text] [Related]
71. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563 [TBL] [Abstract][Full Text] [Related]
74. Insulin pump therapy in children with type 1 diabetes: the dark side of the moon. Scaramuzza AE; Dell'Acqua M; Macedoni M; Zuccotti GV J Diabetes Sci Technol; 2013 Jul; 7(4):1095-7. PubMed ID: 23911194 [No Abstract] [Full Text] [Related]
80. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]